Now showing items 1-4 of 4

    • ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. 

      Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; Patin, EC; Pearson, A; Smith, HG; Paget, JTE; Patel, RR; Foo, S; Bozhanova, G; Ragulan, C; Fontana, E; Desai, K; Wilkins, AC; Sadanandam, A; Melcher, A; McLaughlin, M; Harrington, KJ (2019-06)
      <h4>Purpose</h4>ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on ...
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 

      Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, T; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, CT; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, YM; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, LP; Eeles, R; Attard, G; Lord, CJ; Ashworth, A; Rubin, MA; Knudsen, KE; Feng, FY; Chinnaiyan, AM; Hall, E; de Bono, JS
      Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to ...
    • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 

      Southey, MC; Goldgar, DE; Winqvist, R; Pylkäs, K; Couch, F; Tischkowitz, M; Foulkes, WD; Dennis, J; Michailidou, K; van Rensburg, EJ; Heikkinen, T; Nevanlinna, H; Hopper, JL; Dörk, T; Claes, KB; Reis-Filho, J; Teo, ZL; Radice, P; Catucci, I; Peterlongo, P; Tsimiklis, H; Odefrey, FA; Dowty, JG; Schmidt, MK; Broeks, A; Hogervorst, FB; Verhoef, S; Carpenter, J; Clarke, C; Scott, RJ; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Bolla, MK; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Marme, F; Burwinkel, B; Yang, R; Guénel, P; Truong, T; Menegaux, F; Sanchez, M; Bojesen, S; Nielsen, SF; Flyger, H; Benitez, J; Zamora, MP; Perez, JIA; Menéndez, P; Anton-Culver, H; Neuhausen, S; Ziogas, A; Clarke, CA; Brenner, H; Arndt, V; Stegmaier, C; Brauch, H; Brüning, T; Ko, Y-D; Muranen, TA; Aittomäki, K; Blomqvist, C; Bogdanova, NV; Antonenkova, NN; Lindblom, A; Margolin, S; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Spurdle, AB; Investigators, K; Australian Ovarian Cancer Study Group; Wauters, E; Smeets, D; Beuselinck, B; Floris, G; Chang-Claude, J; Rudolph, A; Seibold, P; Flesch-Janys, D; Olson, JE; Vachon, C; Pankratz, VS; McLean, C; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Kristensen, V; Alnæs, GG; Zheng, W; Hunter, DJ; Lindstrom, S; Hankinson, SE; Kraft, P; Andrulis, I; Knight, JA; Glendon, G; Mulligan, AM; Jukkola-Vuorinen, A; Grip, M; Kauppila, S; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Hollestelle, A; Garcia-Closas, M; Figueroa, J; Chanock, SJ; Lissowska, J; Czene, K; Darabi, H; Eriksson, M; Eccles, DM; Rafiq, S; Tapper, WJ; Gerty, SM; Hooning, MJ; Martens, JWM; Collée, JM; Tilanus-Linthorst, M; Hall, P; Li, J; Brand, JS; Humphreys, K; Cox, A; Reed, MWR; Luccarini, C; Baynes, C; Dunning, AM; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Tessier, DC; Vincent, D; Bacot, F; Simard, J; Dumont, M; Soucy, P; Eeles, R; Muir, K; Wiklund, F; Gronberg, H; Schleutker, J; Nordestgaard, BG; Weischer, M; Travis, RC; Neal, D; Donovan, JL; Hamdy, FC; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Schaid, DJ; Kelley, JL; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Butterbach, K; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Kote-Jarai, Z; Olama, AAA; Benlloch, S; Renner, SP; Hartmann, A; Hein, A; Ruebner, M; Lambrechts, D; Van Nieuwenhuysen, E; Vergote, I; Lambretchs, S; Doherty, JA; Rossing, MA; Nickels, S; Eilber, U; Wang-Gohrke, S; Odunsi, K; Sucheston-Campbell, LE; Friel, G; Lurie, G; Killeen, JL; Wilkens, LR; Goodman, MT; Runnebaum, I; Hillemanns, PA; Pelttari, LM; Butzow, R; Modugno, F; Edwards, RP; Ness, RB; Moysich, KB; du Bois, A; Heitz, F; Harter, P; Kommoss, S; Karlan, BY; Walsh, C; Lester, J; Jensen, A; Kjaer, SK; Høgdall, E; Peissel, B; Bonanni, B; Bernard, L; Goode, EL; Fridley, BL; Vierkant, RA; Cunningham, JM; Larson, MC; Fogarty, ZC; Kalli, KR; Liang, D; Lu, KH; Hildebrandt, MAT; Wu, X; Levine, DA; Dao, F; Bisogna, M; Berchuck, A; Iversen, ES; Marks, JR; Akushevich, L; Cramer, DW; Schildkraut, J; Terry, KL; Poole, EM; Stampfer, M; Tworoger, SS; Bandera, EV; Orlow, I; Olson, SH; Bjorge, L; Salvesen, HB; van Altena, AM; Aben, KKH; Kiemeney, LA; Massuger, LFAG; Pejovic, T; Bean, Y; Brooks-Wilson, A; Kelemen, LE; Cook, LS; Le, ND; Górski, B; Gronwald, J; Menkiszak, J; Høgdall, CK; Lundvall, L; Nedergaard, L; Engelholm, SA; Dicks, E; Tyrer, J; Campbell, I; McNeish, I; Paul, J; Siddiqui, N; Glasspool, R; Whittemore, AS; Rothstein, JH; McGuire, V; Sieh, W; Cai, H; Shu, X-O; Teten, RT; Sutphen, R; McLaughlin, JR; Narod, SA; Phelan, CM; Monteiro, AN; Fenstermacher, D; Lin, H-Y; Permuth, JB; Sellers, TA; Chen, YA; Tsai, Y-Y; Chen, Z; Gentry-Maharaj, A; Gayther, SA; Ramus, SJ; Menon, U; Wu, AH; Pearce, CL; Van Den Berg, D; Pike, MC; Dansonka-Mieszkowska, A; Plisiecka-Halasa, J; Moes-Sosnowska, J; Kupryjanczyk, J; Pharoah, PD; Song, H; Winship, I; Chenevix-Trench, G; Giles, GG; Tavtigian, SV; Easton, DF; Milne, RL (2016-12)
      <h4>Background</h4>The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations ...
    • Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. 

      Mijuskovic, M; Saunders, EJ; Leongamornlert, DA; Wakerell, S; Whitmore, I; Dadaev, T; Cieza-Borrella, C; Govindasami, K; Brook, MN; Haiman, CA; Conti, DV; Eeles, RA; Kote-Jarai, Z (2018-07)
      <h4>Background</h4>Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal. We sought to identify a signature of rare inherited variants that distinguishes between ...